Navigation Links
Japanese Fund Moves Quickly to Invest in Promising Technology Against Malaria, Tuberculosis And Chagas Disease
Date:11/7/2013

are the current gold-standard anti-malarial treatments that combine fast-acting artemisinin derivatives with a long-acting partner drug. The new drug candidate, DSM265, which kills the malaria parasite through inhibition of an essential enzyme, is a compound with a long duration of action that could potentially be part of a new treatment for malaria, with potential for being part of a single dose cure. The compound recently entered clinical phase I studies in healthy human volunteers. If the planned studies show that it works safely and effectively, DSM265 could undergo later-stage development as a new option in the treatment of malaria.

An additional award of approximately US$575,000 was granted to MMV in partnership with Takeda for development and its formulation of ELQ300, an anti-malarial compound that is in earlier stages of development. ELQ300 has the potential to be given once a month to treat and prevent malarial infections, which would make it an important tool in the control of malaria. However, some additional work related to its formulation is needed before it can be tested in patients.

The GHIT Fund will also invest in candidate products for tuberculosis and Chagas disease. For tuberculosis, a disease that causes an estimated 8.6 million new cases and kills about 1.3 million people annually, the Fund will invest US$720,000 for early work on a novel vaccine candidate against tuberculosis being co-developed by the National Institute of Biomedical Innovation, Japan's Create Vaccine Co., Ltd. and Aeras, an international non-profit biotech based in Washington, DC. The vaccine is the first to target the patient's mucous membranes to keep TB from making an entry into the lungs. In mice, the vaccine added protection to BCG, the current vaccine against tuberculosis. BCG was invented nearly 90 years ago and provides insufficient protection to teenagers and adults, the group with the highest TB bu
'/>"/>

SOURCE Global Health Innovative Technology Fund (GHIT Fund)
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Japanese Market for Orthopedic Soft Tissue Repair & Sports Medicine
2. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
3. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
4. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
5. Reimbursement Cuts Will Challenge Japanese Interventional Cardiology Device Market
6. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
7. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
8. Japanese Heart Valve Device Market Growth Will Spike With The Launch of Transcatheter Heart Valves
9. The Japanese Market For Peripheral Vascular Devices Will Be Characterized By New Product Launches In Many Segments
10. The Japanese Embolization Particle Market Will Witness Significant Market Activity And Rapid Growth Due To New Product Approvals
11. SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 The Pennsylvania State Police will ... 27, as part of National Prescription Drug Take-Back Day. ... Take-Back Day is a national initiative, conducted ... aimed at encouraging the public to dispose of expired, ... abuse and theft. From 10 a.m. to ...
(Date:9/23/2014)... 23, 2014 Rising health ... and increasing number of foreign and domestic players in ... India   The ... most high growth potential markets worldwide due to multiple ... among the youth, changing food consumption patterns, increasing diabetic ...
(Date:9/23/2014)... Iowa , Sept. 23, 2014  KemPharm, ... the discovery and development of proprietary new molecular ... a No Objection Letter (NOL) from Health Canada ... for its lead product candidate KP201 ... prodrug in development for acute moderate to moderately ...
Breaking Medicine Technology:India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... Calif., Aug. 2, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the following investor ... Conference Location: Intercontinental Hotel, Boston, MA Presentation ... Wedbush Life Sciences ...
... Mich., Aug. 2, 2011 Perrigo Company (Nasdaq: PRGO;TASE) today ... quarter fiscal 2011 on Tuesday, August 16 , 2011 at ... call at 10:00 a.m. (ET) hosted by Joseph C. Papa, ... call will be available live via webcast to interested parties ...
Cached Medicine Technology:
(Date:9/23/2014)... PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN THE ... The National Institutes of Health is convening a Pathways ... on the long-term effectiveness and potential risks of opioids ... nation,s top experts in the field of pain control ... key NIH scientists who focus on pain related research. ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows all about ... can be treated. , A medically retired Army veteran, ... platoon sustained multiple attacks resulting in five casualties. After ... PTSD and honorably discharged from the Army. , “I ... myself from my friends and family,” recalled O’Farrell, who ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Dr. Connie Casad ... medical practices to new office space at 12200 Park Central ... at the office will be Park Cities Aesthetics, Optimal Health ... , In announcing her move, Dr. Casad said, “The patients’ ... treatment they select, we want them to always feel like ...
(Date:9/23/2014)... used to diagnose lung cancer may not be as reliable ... a new analysis says. One noninvasive way of ... as functional imaging. For lung cancer, a specific type of ... authors. Cancerous tumors generally look different on FDG-PET images ... have cancer, according to background information in the study. But, ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Avid collector Andrew ... 1967 The Doors Eagle Auditorium Seattle concert posters. The Doors ... “Break On Through” that year. The Seattle Eagles Auditorium concert ... “The Doors would return to Eagles Auditorium in November the ... is not known and comes in three colors. The poster ...
Breaking Medicine News(10 mins):Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Dr. Connie Casad Moving to New Office Location 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2
... ... New York personal injury attorney, David Perecman. , ... New York, NY (PRWEB) July 14, 2009 -- Three workers, including a ... accident at a privately operated waste transfer plant in Jamaica, Queens. All three apparently ...
... , , ... Masimo (Nasdaq: MASI ), the inventor of Pulse ... 2009 Silver Medical Design Excellence Award in the general hospital devices ... award recognizes Rad-87,s excellence in medical technology engineering and design as ...
... Five hospital board members honored at annual conference ... Minn., July 14 Five Minnesota hospital ... member certification program. , , The ... issues, to hone their leadership skills and to develop governance best ...
... , , , , ... Inc. announced today that the Dakim(R) BrainFitness(TM) System has now been adopted ... their defenses against dementia and memory loss. Dakim has added 136 new ... brain training system provider in the senior care market. , ...
... Calif., July 14, 2009 A drug similar to one ... psoriasis has been found to rescue memory in mice exhibiting ... hope that a new treatment may be on the horizon ... cause of elderly dementia afflicting more than 5 million people ...
... , , ATLANTA , ... of EyeSite(TM) self-service vision testing kiosks, announced today it will team ... educational experience featured in the kiosks. The EyeSite kiosks contribute ... vision assessments and driving consumers to local eye care professionals for ...
Cached Medicine News:Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 2Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 3Health News:Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award 2Health News:Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award 3Health News:Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award 4Health News:Dakim BrainFitness Now Used in 286 Senior Living Communities, Adding 136 Sites in 12 Months for Dementia-Fighting System 2Health News:Dakim BrainFitness Now Used in 286 Senior Living Communities, Adding 136 Sites in 12 Months for Dementia-Fighting System 3Health News:Drug rescues memory lost to Alzheimer's disease 2Health News:Eyemaginations Partners with SoloHealth to Enhance Public Eye Health Education with EyeSite(TM) Vision Kiosks 2Health News:Eyemaginations Partners with SoloHealth to Enhance Public Eye Health Education with EyeSite(TM) Vision Kiosks 3
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: